急性髓系白血病首次完全缓解患者接受9/10相合无关供者移植联合移植后环磷酰胺预防移植物抗宿主病较双份脐血移植生存更高:欧洲血液和骨髓移植学会急性白血病工作组研究
该回顾性注册研究比较了急性髓系白血病首次完全缓解患者接受双份脐血移植(dCBT,n=209)与9/10相合无关供者移植联合移植后环磷酰胺预防移植物抗宿主病(UD 9/10,n=270)的结局。校正协变量后,dCBT组非复发死亡率更高(HR=2.35),无白血病生存更低(HR=1.5),总生存更低(HR=1.66),复发发生率无显著差异。作者认为,对于缺乏HLA全合供者的AML患者,UD 9/10联合PTCy预防可能优于dCBT。
要点
- 180天II-IV级急性GVHD累积发生率UD 9/10组29% vs dCBT组44%(p=.001)。
- 校正后dCBT组非复发死亡率更高(HR=2.35,95%CI:1.23-4.48;p=.01)。
- 校正后dCBT组总生存更低(HR=1.66,95%CI:1.08-2.55;p=.02)。
核心结论
- 对于首次完全缓解的急性髓系白血病患者,9/10相合无关供者移植联合移植后环磷酰胺预防的结局优于双份脐血移植。
研究设计与样本
- 大型回顾性注册研究,比较双份脐血移植(dCBT,n=209)与9/10相合无关供者移植联合移植后环磷酰胺预防(UD 9/10,n=270)。
- 纳入标准:成人患者、移植时急性髓系白血病首次完全缓解、接受9/10相合无关供者外周血干细胞联合PTCy预防或接受不含PTCy的双份脐血移植、移植时间2013年至2021年、无体内T细胞去除。
主要发现
- 180天II-IV级急性GVHD累积发生率UD 9/10组29% vs dCBT组44%(p=.001)。
- 校正协变量后,dCBT组非复发死亡率更高(HR=2.35,95%CI:1.23-4.48;p=.01)。
- 校正协变量后,dCBT组复发发生率与UD 9/10组无显著差异(HR=1.12,95%CI:0.67-1.86;p=.66)。
- 校正协变量后,dCBT组无白血病生存更低(HR=1.5,95%CI:1.01-2.23;p=.047)。
- 校正协变量后,dCBT组总生存更低(HR=1.66,95%CI:1.08-2.55;p=.02)。
临床怎么用
- 作者认为,这些数据可能支持在缺乏HLA全合供者的急性髓系白血病患者中优先选择9/10相合无关供者移植联合移植后环磷酰胺预防而非双份脐血移植。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The best donor option for acute myeloid leukemia (AML) patients lacking an HLA-matched donor has remained intensively debated. We herein report the results of a large retrospective registry study comparing hematopoietic cell transplantation (HCT) outcomes between double-unit umbilical cord blood transplantation (dCBT, n = 209) versus 9/10 HLA-matched unrelated donor (UD) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis (UD 9/10, n = 270) in patients with AML in first complete remission (CR1). Inclusion criteria consisted of adult patient, AML in CR1 at transplantation, either peripheral blood stem cells (PBSC) from UD 9/10 with PTCy as GVHD prophylaxis or dCBT without PTCy, transplantation between 2013 and 2021, and no in vivo T-cell depletion. The 180-day cumulative incidence of grade II-IV acute GVHD was 29% in UD 9/10 versus 44% in dCBT recipients (p = .001). After adjustment for covariates, dCBT recipients had a higher non-relapse mortality (HR = 2.35, 95% CI: 1.23-4.48; p = .01), comparable relapse incidence (HR = 1.12, 95% CI: 0.67-1.86; p = .66), lower leukemia-free survival (HR = 1.5, 95% CI: 1.01-2.23; p = .047), and lower overall survival (HR = 1.66, 95% CI: 1.08-2.55; p = .02) compared with patients receiving UD 9/10 HCT. In summary, our results suggest that transplantation outcomes are better with UD 9/10 with PTCy-based GVHD prophylaxis than with dCBT for AML patients in CR1. These data might support the use of UD 9/10 with PTCy-based GVHD prophylaxis over dCBT in AML patients lacking an HLA-matched donor.
引用
- Baron F, Labopin M, Versluis J, et al. Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024. PMID: 39215605. doi:10.1002/ajh.27466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。